Lemulin-600 600 mg
Lefamulin
Category: Tablet
Manufacturer: Renata Limited
Allopathic
MFG. Licence No. Biological
045
MFG. Licence No. Non-Biological
197
Address
Plot No. 1, Sec-7, Milk Vita Road, Mirpur, Dhaka.
Price: 7650.0 ৳
Strip
Medicine Selling service is not available yet.
Related Medicines
Indicated for treatment of, community-acquired bacterial pneumonia (CABP), in adults caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydophila pneumoniae
Lemulin-600 should not be used in patients with known hypersensitivity to lefamulin or any other members of the pleuromutilin antibiotic class, or any of the components of Xenleta.
Adult Dose:
Community Acquired Bacterial Pneumonia
Indicated for treatment of community-acquired bacterial pneumonia (CABP) in adults caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae
150 mg IV q12hr OR
600 mg PO q12 hr
Duration of treatment: 5-7 days
Lefamulin should not be used in patients with known hypersensitivity to lefamulin or any other members of the pleuromutilin antibiotic class, or any of the components of Xenleta.
The most common adverse reactions reported in patients taking lefamulin included diarrhea, nausea, reactions at the injection site, elevated liver enzymes and vomiting.
Precaution:
Lefamulin has the potential to cause a change on an ECG reading (prolonged QT interval). Patients with prolonged QT interval, patients with certain irregular heart rhythms (arrhythmias), patients receiving treatment for certain irregular heart rhythms (antiarrhythmic agents), and patients receiving other drugs that prolong the QT interval should avoid lefamulin.
First-in-class semi-synthetic pleuromutilin antibiotic; selectively inhibits bacterial translation by binding to the peptidyl transferase component of the ribosome 50S subunit
Based on findings of fetal harm in animal studies, pregnant women and women who could become pregnant should be advised of the potential risks of lefamulin to a fetus. Women who could become pregnant should be advised to use effective contraception during treatment with lefamulin and for two days after the final dose.
Samm Care